Table 1.
Demographic/baseline characteristics: by presence/absence of pain at baseline (as rated by Likert pain scale)
| |
‘No’ pain (n = 80) (pain score 0) |
‘Any’ pain (n = 187) |
|
|---|---|---|---|
|
(pain score ≥1) | |||
|
‘Mild’ pain (n = 87) |
‘Moderate-to-severe’ pain (n = 100) |
||
| (pain score 1–3) | (pain score ≥4) | ||
| Age, years |
66.4 ± 9.3 (37–86) |
63.8 ± 9.8 (37–85); (p = 0.048) |
|
| |
|
63.1 ± 10.4 (37–85); (p = 0.032) |
64.5 ± 9.3 (40–83); (p = 0.175) |
| Female |
23 (29) |
69 (37); (p = 0.199) |
|
| |
|
23 (26); (p = 0.738) |
46 (46); (p = 0.018) |
| Time since diagnosis, years |
4.7 ± 4.4 (0.0–22.9) |
4.9 ± 4.4 (0.0–25.6); (p = 0.820) |
|
| |
|
4.5 ± 3.8 (0.0–17.2); (p = 0.765) |
5.1 ± 4.9 (0.0–25.6); (p = 0.555) |
| Taking levodopa (advanced PD) |
62 (78) |
156 (83); (p = 0.252) |
|
| |
|
70 (80); (p = 0.639) |
86 (86); (p = 0.138) |
| UPDRS III total score |
28.3 ± 11.1 |
31.3 ± 13.5; (p = 0.075) |
|
| |
|
29.2 ± 11.9; (p = 0.621) |
33.2 ± 14.5; (p = 0.013) |
| PDSS-2 total score |
16.0 ± 7.8 |
21.2 ± 9.8; (p <0.0001) |
|
| 18.6 ± 9.2; (p = 0.048) | 23.5 ± 9.8; (p <0.0001) | ||
Data are mean ± SD (range) or number of patients (%). Data are presented for the FAS.
P values (t-test for continuous data, Chi-square test for categorical data; exploratory analyses) are reported for patients with ‘Any’ pain, ‘Mild’ pain, and ‘Moderate-to-severe’ pain vs patients with ‘No’ pain at baseline (assessed by the Likert pain scale).
FAS: full analysis set; PD: Parkinson’s disease; PDSS-2: Parkinson’s Disease Sleep Scale; SD: standard deviation; UPDRS III: Unified Parkinson’s Disease Rating Scale.